The probiotic strain in Qiara Lactobacillus fermentum CECT5716 has been isolated from human breastmilk and is well supported by publicly available research spanning over 15 years. Health professionals may login for links to all research on Lactobacillus fermentum CECT5716. For further information, seek advice from your healthcare practitioner.

1. Ruth Blanco-RojoJosé Maldonado, Monika Schaubeck, Metehan Özen, Eduardo López-Huertas and Mónica Olivares."Beneficial Effects of Limosilactobacillus fermentum CECT 5716 Administration to Infants Delivered by Cesarean Section" Frontiers in Pediatrics., 07 July 2022 Sec. Pediatric Gastroenterology, Hepatology and Nutrition

2. Belén Pastor-Villaescusa, Ruth Blanco-Rojo and Mónica Olivares. Evaluation of the Effect of Limosilactobacillus fermentum CECT5716 on Gastrointestinal Infections in Infants: A Systematic Review and Meta-Analysis Microorganisms 20219(7), 1412; Published: 30 June 2021

3.J. Maldonado, M. Gil-Campos, J. A. Maldonado-Lobón, M. R. Benavides et al Evaluation of the safety, tolerance and efficacy of 1-year consumption of infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40 or Bifidobacterium breve CECT7263: a randomized controlled trial BMC Pediatrics volume 19, Article number: 361 (2019)

4.Gil-Campos Mercedes, López Miguel Ángel, Rodriguez-Benítez M Victoria, Romero Julio, Roncero Inés, Linares M Dolores, Maldonado Jose, et al. 2012. "Lactobacillus fermentum CECT 5716 is safe and well tolerated in infants of 1-6 months of age: a randomized controlled trial." Pharmacological research : the official journal of the Italian Pharmacological Society 65 (2): 231-8. doi:10.1016/j.phrs.2011.11.016.

5. Maldonado, J etal. 2012. "Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants.". J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):55-61. doi: 10.1097/MPG.0b013e3182333f18.